Who We Are:

EyeGate Pharma (NASDAQ: EYEG) is a clinical-stage pharmaceutical company developing and commercializing products for treating inflammatory and immune diseases. PP-001 is a next-generation, non-steroidal, immuno-modulatory and small-molecule inhibitor of Dihydroorotate Dehydrogenase (“DHODH”) with best-in-class picomolar potency and a validated immune modulating mechanism. In addition, EyeGate is developing the Ocular Bandage Gel (“OBG”), a modified form of the natural polymer hyaluronic acid, designed to protect the ocular surface to permit re-epithelialization of the cornea and improve ocular surface integrity. OBG has unique properties that help hydrate and protect the ocular surface.

Our Pipeline:

EyeGate is in the clinic with both PP-001 and OBG for treating various ocular surface diseases, including dry eye, conjunctivitis and wound healing. We are also formulating PP-001 for treating certain systemic diseases. Learn More